^
Association details:
| Biomarker: | KDR Q472H + KIT M541L |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Caprelsa (vandetanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study
Published date:
03/12/2021
Excerpt:
Patients were enrolled at five dose levels using 100 mg of VAN orally daily and 2.5 mg of EV orally daily for 28 days as starting doses…one patient with epithelioid sarcoma harboring single nucleotide polymorphisms (SNPs), kinase insert domain receptor (KDR) Q472H, and KIT M541L aberrations experienced a 74% reduction in tumor size when compared with baseline.
Secondary therapy:
everolimus
DOI:
10.1016/j.esmoop.2021.100079
